2016 | 2015 | 2014 | 2013
February 11, 2016Incyte Reports 2015 Fourth-Quarter and Year-End Financial Results, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs
$182 million of 2015 fourth-quarter net product revenues from Jakafi® (ruxolitinib), representing 72 percent growth over the same period last year and $601 million of 2015 full-year net product revenues from Jakafi, representing 68 percent growth over last year 2016 guidance for Jakafi net product revenues in the range of $800 million to $815 million, reflecting expectations for continued growth in underlying demand in myelofi... 
Printer Friendly Version
February 11, 2016Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 11, 2016-- Incyte Corporation (Nasdaq: INCY) announced today its decision to discontinue the Phase 3 study (JANUS 1) of ruxolitinib or placebo in combination with capecitabine for the second-line treatment of patients with advanced or metastatic pancreatic cancer. The decision to stop the study was made after a planned interim analysis of JANUS 1 demonstrated that ruxolitinib plus capecitabine did not show a suffic... 
Printer Friendly Version
January 27, 2016Incyte Announces Decision to Stop Phase 2 Sub-study of Ruxolitinib Plus Regorafenib in Patients with Metastatic Colorectal Cancer and High CRP
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 27, 2016-- Incyte Corporation (Nasdaq: INCY) announced today that the Phase 2 sub-study of ruxolitinib or placebo in combination with regorafenib in patients with relapsed or refractory metastatic colorectal cancer (CRC) and high C-reactive protein (CRP) will be stopped early. The decision to stop the sub-study was made after a planned interim analysis of the high CRP subgroup demonstrated that ruxolitinib plus reg... 
Printer Friendly Version
January 21, 2016Incyte to Report Fourth Quarter/Year-End Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 21, 2016-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its fourth quarter 2015 financial results conference call and webcast for 10:00 a.m. ET on Thursday, February 11, 2016. The schedule for the press release and conference call/webcast is as follows:       ... 
Printer Friendly Version
January 19, 2016Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis
INDIANAPOLIS, Jan. 19, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that Lilly has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid arthritis (RA). As a result, Incyte will receive a milestone payment of $35 million from Lilly related to the NDA submission. If baricitinib ... 
Printer Friendly Version
January 11, 2016Incyte Presents Significant Progress in its Development Portfolio
Rapidly advancing portfolio with 13 development molecules being investigated as monotherapy and in combination across multiple indications Two new development molecules—an LSD1 inhibitor and an anti-GITR agonist—added to the portfolio and expected to enter the clinic in first-half of 2016 Rich news flow from pivotal and proof-of-concept programs expected in 2016 Webcast present... 
Printer Friendly Version
January 11, 2016Incyte and AstraZeneca Announce New Lung Cancer Clinical Trial Collaboration
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 11, 2016-- Incyte Corporation (Nasdaq:INCY) and AstraZeneca (NYSE:AZN) today announced a new collaboration to evaluate the efficacy and safety of Incyte’s Janus-associated kinase (JAK) 1 inhibitor, INCB39110, in combination with AstraZeneca’s next generation epidermal growth factor receptor (EGFR) inhibitor, Tagrisso® (osimertinib). The combination will be assessed as a second-line treatment for patients wit... 
Printer Friendly Version
RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet